News Sobi stays on its acquisitive streak with $915m Dova deal Sweden’s Sobi has added another already-marketed product to its rare disease portfolio via a $29 per share takeover of Dova
News Vaxcyte's pneumococcal jab exceeds expectations Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
